CD274 and neoplasm: On the other hand, the ischemia and cytotoxic damage that TACE causes to the tumor may make it easier to prime de novo T-cell responses against tumor-associated antigens, thus enabling an increased activity of PD-1/PD-L1 inhibitors [17, 18].